Hyperthyroxinemia: Clinical Trials

1 trial for Hyperthyroxinemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Active not recruiting 1

Follow Hyperthyroxinemia: new trials by email Literature Review of Hyperthyroxinemia trials Research Report on Hyperthyroxinemia

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Resmetirom - Non-Alcoholic Fatty Liver Disease
Phase 3Active not recruitingMadrigal Pharmaceuticals, Inc.8102021-07-092026-05-27

Narrower conditions

Dyslipidemias (1)  ·  Fibrosis (1)  ·  Hyperlipidemias (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Thyroid Hormone Resistance Syndrome (1)

Broader conditions

Digestive System Diseases (1)  ·  Endocrine System Diseases (1)  ·  Fatty Liver (1)  ·  Lipid Metabolism Disorders (1)  ·  Liver Diseases (1)  ·  Metabolic Diseases (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Thyroid Diseases (1)

Interventions

resmetirom (1)

Sponsors

Madrigal Pharmaceuticals, Inc. (1)

Countries

Puerto Rico (1)  ·  United States (1)

Top investigators

Tom Hare, MD (1)

Results publications

PMID 37786277